{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:25:08Z","timestamp":1791228308780,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.urology.2022.05.003","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T01:56:46Z","timestamp":1652752606000},"page":"140-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Impact of Duration of Antibiotic Prophylaxis on Incidence of UTI after OnabotulinumtoxinA Injection"],"prefix":"10.1016","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7983-6411","authenticated-orcid":false,"given":"Sarah","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Zillioux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard B.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Slopnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2022.05.003_bib0001","unstructured":"American Urological Association. Diagnosis and Treatment of Non-Neurogenic Overactive Bladder (OAB) in Adults: an AUA\/SUFU Guideline (2019). Available at: https:\/\/www.auanet.org\/guidelines\/overactive-bladder-(oab)-guideline. Accessed October 1, 2020."},{"key":"10.1016\/j.urology.2022.05.003_bib0002","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.acuro.2013.02.002","article-title":"EAU guidelines on surgical treatment of urinary incontinence","volume":"37","author":"Lucas","year":"2013","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.urology.2022.05.003_bib0003","first-page":"198","article-title":"Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: state of the art","volume":"8","author":"Nitti","year":"2006","journal-title":"Rev Urol"},{"key":"10.1016\/j.urology.2022.05.003_bib0004","unstructured":"American Urological Association. AUA\/SUFU guideline on adult neurogenic lower urinary tract Dysfunction. Available at:https:\/\/www.auanet.org\/guidelines\/guidelines\/adult-neurogenic-lower-urinary-tract-dysfunction. Accessed April 26, 2022."},{"key":"10.1016\/j.urology.2022.05.003_bib0005","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2022.05.003_bib0006","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.eururo.2013.10.033","article-title":"An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders","volume":"65","author":"Mangera","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2022.05.003_bib0007","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2022.05.003_bib0008","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/nau.23034","article-title":"Use of prophylactic antibiotics for intra-vesicle Botox\u00ae injection","volume":"36","author":"Khan","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2022.05.003_bib0009","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/JU.0000000000000509","article-title":"Best practice statement on urologic procedures and antimicrobial prophylaxis","volume":"203","author":"Lightner","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2022.05.003_bib0010","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s11255-018-1971-1","article-title":"Comparison of guideline recommendations for antimicrobial prophylaxis in urologic procedures: variability, lack of consensus, and contradictions","volume":"50","author":"Ivan","year":"2018","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.urology.2022.05.003_bib0011","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.urology.2019.09.030","article-title":"Safety of intradetrusor OnabotulinumtoxinA (BTX-A) injection in the asymptomatic patient with a positive urine dip","volume":"135","author":"Derisavifard","year":"2020","journal-title":"Urology"},{"key":"10.1016\/j.urology.2022.05.003_bib0012","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1086\/509845","article-title":"Reduction in surgical antibiotic prophylaxis expenditure and the rate of surgical site infection by means of a protocol that controls the use of prophylaxis","volume":"27","author":"Gomez","year":"2006","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.urology.2022.05.003_bib0013","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/502074","article-title":"Clinical, microbiological, and economic benefit of a change in antibiotic prophylaxis for cardiac surgery","volume":"23","author":"Spelman","year":"2002","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.urology.2022.05.003_bib0014","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.0001-6349.2005.00583.x","article-title":"Prospective randomized comparison of single-dose versus 1-day cefazolin for prophylaxis in gynecologic surgery","volume":"84","author":"Su","year":"2005","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.urology.2022.05.003_bib0015","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/JU.0000000000000296","article-title":"Recurrent uncomplicated urinary tract infections in women: AUA\/CUA\/SUFU guideline","volume":"202","author":"Anger","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2022.05.003_bib0016","doi-asserted-by":"crossref","unstructured":"Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. AM J Surg 2005; 189: 395\u2013404.","DOI":"10.1016\/j.amjsurg.2005.01.015"},{"key":"10.1016\/j.urology.2022.05.003_bib0017","unstructured":"American Urological Association. Urologic surgery antimicrobial prophylaxis (2012). Available at:https:\/\/www.auanet.org\/guidelines\/archived-documents\/antimicrobial-prophylaxis-best-practice-statement. Accessed January 28, 2022."},{"key":"10.1016\/j.urology.2022.05.003_bib0018","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0022-5347(01)69088-8","article-title":"Prophylactic antibiotic use in transurethral prostatic resection: a meta-analysis","volume":"167","author":"Berry","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2022.05.003_bib0019","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.eururo.2008.03.033","article-title":"Antibiotic prophylaxis in urologic procedures: a systematic review","volume":"54","author":"Bootsma","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2022.05.003_bib0020","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/JU.0000000000001513","article-title":"Antimicrobial prophylaxis for postoperative urinary tract infections in transurethral resection of bladder tumors: a systematic review and meta-analysis","volume":"205","author":"Bausch","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2022.05.003_bib0021","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00192-018-3721-4","article-title":"What is the ideal antibiotic prophylaxis for intravesically administered Botox injection? A comparison of two different regimens","volume":"30","author":"Houman","year":"2019","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.urology.2022.05.003_bib0022","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s00192-020-04230-7","article-title":"A comparison of antibiotic prophylaxis regimens to decrease the risk of post-procedure urinary tract infection after onabotulinum toxin A injection","volume":"31","author":"Bickhaus","year":"2020","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.urology.2022.05.003_bib0023","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/j.1464-410X.2010.09435.x","article-title":"Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment","volume":"106","author":"Mouttalib","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2022.05.003_bib0024","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1001\/jama.2016.14617","article-title":"OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women","volume":"316","author":"Amundsen","year":"2016","journal-title":"JAMA"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429522003703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429522003703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T02:45:11Z","timestamp":1758768311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429522003703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":24,"alternative-id":["S0090429522003703"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2022.05.003","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Duration of Antibiotic Prophylaxis on Incidence of UTI after OnabotulinumtoxinA Injection","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2022.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}